# US 2013/0274138 A1 · Gene signatures for prediction of therapy-related myelodysplasia and methods for identification of patients at risk for development of the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0274138 A1
- Document ID: US20130274138A1
- Status: Published application
- Kind: A1
- Application number: 13/913,077
- Filed: 2013-06-07
- Published: 2013-10-17
- Earliest claimed: 2010-12-08
- Assignees: Fred Hutchinson Cancer Research Center; City of Hope
- Applicants: Fred Hutchinson Cancer Research Center; City of Hope
- Inventors: Ravi Bhatia; Smita Bhatia; Stephen Forman; Jerald P. Radich; Liang Li; Min Li; Lue Ping Zhao
- Web page: https://patentgrep.com/patent/US20130274138A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

In one embodiment, a gene expression signature for predicting risk of developing therapy-related myelodysplasia or acute myeloid leukemia (t-MDS/AML) after autologous hematopoietic cell transplantation (aHCT) is provided. In another embodiment, a method for predicting a risk for development of t-MDS/AML after aHCT is provided. Such a method may include providing a biological sample that contains CD34 cells from a subject; detecting a test expression level of a set of two or more genes of a gene expression signature; comparing the test expression level of a set of corresponding training expression levels that include a training case expression level and a training control expression level; and predicting a high risk of developing t-MDS/AML when the test expression level is at or about the training case expression level or predicting a low risk of developing t-MDS/AML when the test expression level is at or about the training control expression level.

## Claims

### Claim 1

A gene expression signature for predicting risk of developing therapy-related myelodysplasia or acute myeloid leukemia (t-MDS/AML) after autologous hematopoietic cell transplantation (aHCT) comprising a set of two or more genes associated with the development of t-MDS/AML.

### Claim 2 (depends on 1)

The gene expression signature of claim 1, wherein the two or more genes associated with the development of t-MDS/AML are expressed in CD34+ cells.

### Claim 3 (depends on 1)

The gene expression signature of claim 1, wherein the two or more genes associated with the development of t-MDS/AML are selected from genes related to mitochondrial oxidative phosphorylation, protein synthesis, cell cycle, DNA repair, cellular response to injury, G-protein coupled receptors, hematopoietic regulation, cell adhesion, cell communication, immediate-early stress response, xenobiotic processing, hematopoietic stem cell growth and regulation.

### Claim 4 (depends on 1)

The gene expression signature of claim 1, where in the two or more genes associated with the development of t-MDS/AML are selected from the group consisting of NR4A2, FOS, EGR1, CARD6, PEX11B, EGR3, EGR4, MRPL15, SLC7A11, REEP1, FOSB, GOLGA5, ACTL6A, GOLPH3L, CCDC99, SMAD7, SHMT2, LRPPRC, CDCA4, PDIA4, GOT1, RTN3, KLF2, JUN, STK17B, PSMC2, LRBA, XPOT, ZYG11B, ZNF137, GEM, PGRMC2, ARL61P6, SLC2A3P1, NR4A3, RGS2, NRIP3 and SLC26A2.

### Claim 5 (depends on 1)

The gene expression signature of claim 1, where in the two or more genes associated with the development of t-MDS/AML are NR4A2, FOS, EGR1, CARD6, PEX11B, EGR3, EGR4, MRPL15, SLC7A11, REEP1, FOSB, GOLGA5, ACTL6A, GOLPH3L, CCDC99, SMAD7, SHMT2, LRPPRC, CDCA4, PDIA4, GOT1, RTN3, KLF2, JUN, STK17B, PSMC2, LRBA, XPOT, ZYG11B, ZNF137, GEM, PGRMC2, ARL61P6, SLC2A3P1, NR4A3, RGS2, NRIP3 and SLC26A2.

### Claim 6 (depends on 2)

The gene expression signature of claim 2, wherein the two or more genes are upregulated in a subject at risk for developing t-MDS/AML, downregulated in a subject at risk for developing t-MDS/AML or a combination thereof.

### Claim 7

A method for predicting a subject's risk for developing therapy-related myelodysplasia or acute myeloid leukemia (t-MDS/AML) after autologous hematopoietic cell transplantation (aHCT) comprising:
detecting a test expression level of a set of two or more genes of a gene expression signature in a biological sample from a subject;
comparing the test expression level of a set of corresponding training expression levels that include a training case expression level and a training control expression level; and
predicting a high risk of developing t-MDS/AML when the test expression level is at or about the training case expression level or predicting a low risk of developing t-MDS/AML when the test expression level is at or about the training control expression level.

### Claim 8 (depends on 7)

The method of claim 7, wherein the biological sample is a blood sample, a peripheral blood stem cell sample or a bone marrow sample.

### Claim 9 (depends on 7)

The method of claim 7, wherein the subject has Hodgkin lymphoma or non-Hodgkin lymphoma.

### Claim 10 (depends on 7)

The method of claim 7, wherein the two or more genes of the gene signature are expressed in CD34+ cells.

### Claim 11 (depends on 7)

The method of claim 7, wherein the two or more genes of the CD34+ cell gene expression signature are selected from genes related to mitochondrial oxidative phosphorylation, protein synthesis, cell cycle, DNA repair, cellular response to injury, G-protein coupled receptors, hematopoietic regulation, cell adhesion, cell communication, immediate-early stress response, xenobiotic processing, hematopoietic stem cell growth.

### Claim 12 (depends on 10)

The method of claim 10, wherein the two or more genes of the CD34+ cell gene expression signature are selected from the group consisting of NR4A2, FOS, EGR1, CARD6, PEX11B, EGR3, EGR4, MRPL15, SLC7A11, REEP1, FOSB, GOLGA5, ACTL6A, GOLPH3L, CCDC99, SMAD7, SHMT2, LRPPRC, CDCA4, PDIA4, GOT1, RTN3, KLF2, JUN, STK17B, PSMC2, LRBA, XPOT, ZYG11B, ZNF137, GEM, PGRMC2, ARL61P6, SLC2A3P1, NR4A3, RGS2, NRIP3 and SLC26A2.

### Claim 13 (depends on 10)

The method of claim 10, wherein the two or more genes of the CD34+ cell gene expression signature are NR4A2, FOS, EGR1, CARD6, PEX11B, EGR3, EGR4, MRPL15, SLC7A11, REEP1, FOSB, GOLGA5, ACTL6A, GOLPH3L, CCDC99, SMAD7, SHMT2, LRPPRC, CDCA4, PDIA4, GOT1, RTN3, KLF2, JUN, STK17B, PSMC2, LRBA, XPOT, ZYG11B, ZNF137, GEM, PGRMC2, ARL61P6, SLC2A3P1, NR4A3, RGS2, NRIP3 and SLC26A2.

### Claim 14 (depends on 7)

The method of claim 7, wherein the training case expression level is derived from a population of subjects that developed t-MDS/AML after aHCT.

### Claim 15 (depends on 7)

The method of claim 7, wherein the training control expression level is derived from a population of subjects that did not develop t-MDS/AML after aHCT.

### Claim 16

A kit to predict a subject's risk of developing t-MDS/AML comprising a set of detection agents capable of detecting a test expression level of a set of two or more genes of a CD34+ cell gene expression signature.

### Claim 17 (depends on 16)

The kit of claim 16, wherein the subject has Hodgkin lymphoma or non-Hodgkin lymphoma.

### Claim 18 (depends on 16)

The kit of claim 16, wherein the two or more genes of the CD34+ cell gene expression signature are selected from genes related to mitochondrial oxidative phosphorylation, protein synthesis, cell cycle, DNA repair, cellular response to injury, G-protein coupled receptors, hematopoietic regulation, and cell adhesion and communication.

### Claim 19 (depends on 16)

The kit of claim 16, wherein the two or more genes of the CD34+ cell gene expression signature are selected from the group consisting of NR4A2, FOS, EGR1, CARD6, PEX11B, EGR3, EGR4, MRPL15, SLC7A11, REEP1, FOSB, GOLGA5, ACTL6A, GOLPH3L, CCDC99, SMAD7, SHMT2, LRPPRC, CDCA4, PDIA4, GOT1, RTN3, KLF2, JUN, STK17B, PSMC2, LRBA, XPOT, ZYG11B, ZNF137, GEM, PGRMC2, ARL61P6, SLC2A3P1, NR4A3, RGS2, NRIP3 and SLC26A2.

### Claim 20 (depends on 16)

The kit of claim 16, wherein the two or more genes of the CD34+ cell gene expression signature are NR4A2, FOS, EGR1, CARD6, PEX11B, EGR3, EGR4, MRPL15, SLC7A11, REEP1, FOSB, GOLGA5, ACTL6A, GOLPH3L, CCDC99, SMAD7, SHMT2, LRPPRC, CDCA4, PDIA4, GOT1, RTN3, KLF2, JUN, STK17B, PSMC2, LRBA, XPOT, ZYG11B, ZNF137, GEM, PGRMC2, ARL61P6, SLC2A3P1, NR4A3, RGS2, NRIP3 and SLC26A2.
